Radhakrishnan, Suresh <br/><br/>
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.  [electronic resource] 

 -  Human gene therapy  Oct 2010 
 - 1311-25 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-7422 
<br/><br/><label>Standard No.: </label>10.1089/hum.2010.019  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenovirus E1A Proteins--genetics<br/>Adenovirus E1B Proteins--genetics<br/>Adenoviruses, Human--drug effects<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Cell Cycle--drug effects<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Combined Modality Therapy<br/>Docetaxel<br/>Flow Cytometry<br/>Gene Expression<br/>Genes, p53<br/>Humans<br/>Immunoblotting<br/>Male<br/>Mice<br/>Mice, Nude<br/>Mitoxantrone--pharmacology<br/>Neoplasm Transplantation<br/>Oncolytic Virotherapy--methods<br/>Oncolytic Viruses--drug effects<br/>Polymerase Chain Reaction<br/>Prostatic Neoplasms--drug therapy<br/>Retinoblastoma Protein--metabolism<br/>Taxoids--pharmacology<br/>Transplantation, Heterologous<br/>Tumor Suppressor Protein p53--metabolism<br/>Virus Replication--drug effects